TrialOncotarget2015

Heterogeneous chromosome 12p deletion is an independent adverse prognostic factor and resistant to bortezomib-based therapy in multiple myeloma.

Fei Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.